Values First Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Values First Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,101	Closed	-$225K	–	365
2023 Q1	$225K	Sell	2,101 -4,596	-69%	-$529K	0.14%	131
2022 Q4	$737K	Sell	6,697 -1,892	-22%	-$123K	0.51%	60
2022 Q3	$507K	Buy	8,589 +682	+9%	+$31.2K	0.36%	83
2022 Q2	$223K	Buy	7,907 +1,899	+32%	+$55K	0.16%	128
2022 Q1	$227K	Buy	+6,008	New	+$237K	0.14%	142

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Values First Advisors's RXDX Position: Q2 2023 in Review

Values First Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,101 shares — an estimated $225K sold.

Values First Advisors first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $737K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Values First Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Values First Advisors sold 2,101 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $225K.
Values First Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Values First Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $737K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.